A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-T
Completed
Conditions studied: Castrate Refractory Metastatic Prostate Cancer (mCRPC)
In brief
Radiation in combination with Provenge based immunotherapy may improve outcomes seen on imaging as well as immunologic monitoring. This study will assess the effect of radiation therapy to augment anti-tumor responses from immune therapy with Provenge.
Key facts
- Study ID
- NCT02232230
- Run by
- GenesisCare USA
- People needed
- 20
- Starts
- 2014-06-01
- Expected to finish
- 2018-06-05
- Last updated by the study team
- 2019-01-09
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
Where it is running
- 21st Century Oncology — Scottsdale, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.